MP1: CORRECTING ATHEROGENIC EFFECTS OF LUPUS PLASMA ON MACROPHAGES WITH RESVERATROL AND MYCOPHENOLATE

Purpose of StudyPremature atherosclerosis with coronary artery disease is a major cause of morbidity in Systemic Lupus Erythematosus (SLE). SLE patient plasma induces a pro-atherogenic profile of cholesterol transport genes in macrophages. A common immunosuppressive treatment for SLE, mycophenolate (MMF) reduces scavenger receptors thus reducing lipid influx. We have demonstrated atheroprotective properties of the polyphenol resveratrol on cholesterol efflux. This study determines whether MMF and resveratrol work synergistically to regulate cholesterol transport in macrophages exposed to pro-atherogenic SLE plasma.Methods UsedTHP-1 human macrophages (106/ml) were incubated in 10% SLE plasma with: media (control); MMF (1 µg/ml); resveratrol (50 µM); and MMF+resveratrol. After 24 h incubation, total RNA and protein were isolated. Message level of scavenger receptors CD36, LOX1, and SRA1; and efflux proteins 27-hydroxylase, ATP binding cassette transporter (ABC)A1, and ABCG1 were evaluated by QRT-PCR and confirmed by immunoblot. Cholesterol efflux was measured by Amplex Red Cholesterol Assay kit run±cholesterol esterase.Summary of ResultsIn 10% SLE plasma, MMF suppressed efflux genes ABCA1 and ABCG1 (58.38±3.5% and 72.98±3.3%) vs. SLE plasma alone (p